Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Los Angeles, CA (PRWEB) September 23, 2014 ... on the Inc. 500|5000 list of the fastest-growing ... growth has been acknowledged yet again by Inc. Magazine,” ExakTime ... the Inc. 5000 list by posting a three-year growth rate ... its workforce in that time by more than 40 percent. ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Proove ... medicine, presented industry leading research and data on the ... at the American Academy of Pain Management’ ... in Phoenix, Arizona at the , Proove ... between gender and genetic predisposition to opioid misuse risk ...
(Date:9/23/2014)... 2014 Follow us on ... popularity the world over, due to its use ... the marketplace is expected to come from increasing ... countries. Several sub-Saharan countries in the African continent, ... implemented genetically engineered crop production strategies. Rising focus ...
(Date:9/23/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to date to $5 million. The orders are all odour ... "We continue to see new orders coming in," said ... our backlog has climbed to over $11 million." ... clean technology company that designs, manufactures and distributes a comprehensive ...
Breaking Biology Technology:ExakTime Makes Inc. 5000 List for the Fifth Time 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... (NASDAQ: HALO ) will be presenting at the ... th Annual Roth Conference in Dana Point on March ... Chief Financial Officer of Halozyme Therapeutics, will provide a corporate ... Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. ...
... NEW YORK, March 7, 2012 Medtrack One View, a ... for the life science industry will be available for demonstration ... of the show will be among the first to view ... View solution gives clients the ability to identify in- and ...
... leaders from across California,s life sciences industry will converge ... by Patients on March 8-9. The conference focus is ... and collaborative research. For the first time, ... California,s life sciences companies. CALBIO2012: Driven by Patients will ...
Cached Biology Technology:Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March 2Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting 2First Statewide Biotech Meeting Focuses on Patient Access, Innovation 2
(Date:9/23/2014)... turn it is to do the washing up, negotiating rights ... as many students returning to university for the new academic ... house can be a tricky business. , And now research ... new technology to allow people to monitor their energy usage ... tension. , The study by a team of technology experts ...
(Date:9/23/2014)... of animals and plants. The central problem in pattern ... a reliable manner to give specific spatial patterns of ... formation is a classic paradigm in developmental biology. Cell ... flag, is caused by a gradient of a signalling ... of the morphogen a "blue", "white" or "red" gene ...
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
Breaking Biology News(10 mins):Smart meters could cause conflict for housemates, study shows 2Smart meters could cause conflict for housemates, study shows 3Recreating the stripe patterns found in animals by engineering synthetic gene networks 2Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3
... make bread taste pleasantly salty without adding more salt? Change ... They report in ACS, Journal of Agricultural and Food ... can make people perceive bread as having saltier taste. The ... which is a risk factor for high blood pressure and ...
... the wafer trapdoor genus Fufius F. minusculus ... discovery of the three new species, published in the open access ... the morphological variability of the species in this little known mygalomorph ... known also as wafer trapdoor spiders. Many, but not all, make ...
... OAK BROOK, Ill. Data from computed tomography (CT) scans ... copies of fossilized bones, according to new research published online ... stored in plaster casts, or jackets, to protect them from ... of the plaster and all the sediment surrounding it, which ...
Cached Biology News:3 new wafer trapdoor spiders from Brazil 2Researchers use CT and 3-D printers to recreate dinosaur fossils 2
... basic power supply are used for submerged horizontal ... This Model 96 cell includes a buffer tank, ... with fluorescent ruler, and a gel caster. The ... provides output of 10-300 V, 4-400 mA, and ...
... clear advantages over traditional electrophoresis for ... mutation analysis, and size polymorphisms analysis. ... connectivity is ideal for basic research, ... The P/ACE Series automated capillary electrophoresis ...
... Capillary Electrophoresis System uses revolutionary technology ... (SPE), urine protein electrophoresis and immunofixation/subtraction ... analysis. The system is truly automated, ... no staining to process patient samples. ...
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
Biology Products: